Latest messages for CancerCompass discussion http://www.cancercompass.com/message-board/message/all,10308,0.htm Sun, 22 Nov 2009 00:00:00 GMT Sun, 22 Nov 2009 00:00:00 GMT http://backend.userland.com/rss RSS.NET: http://www.rssdotnet.com/ more information about Dr. Gonzalez's therapy:http://www.cancer.gov/cancertopics/pdq/cam/gonzalez/Patient/ Wunderchu Wed, 28 Mar 2007 00:00:00 GMT And to add to that...anyone considering Dr. Gonzales regimen should not hesitate to contact him.  Visit his web site for specific instructions on how to present your case to him for review.I presented my mother's case after she was diagnosed with State IV PC in October, 2006.  I followed the guidelines set forth on his web site and sent the information to his NY office via overnight UPS mail.  By the end of business the following day I had a reply.  Unfortunately, he was not willing to take on my mother's case.  We did not realize it at the time, but her disease was too far advanced for his regimen.  However, I was impressed by his promptness, and I would encourage ANYONE dealing with a similar situation to contact him.  I actually do know someone who did his program many years ago and she speaks very highly of him and she is thriving today.  (She did not have PC, I believe it was uterine cancer.)  Best of luck to all! Garagegirl Tue, 13 Mar 2007 00:00:00 GMT After reading these paragraphs, I was intrigued:  Dr. Nicholas J. Gonzalez: "In July 1993, the then Associate Director for the Cancer Therapy Evaluation Program at the National Cancer Institute, Dr. Michael Friedman, invited me to present selected cases from my own practice as part of an NCI effort to evaluate non-traditional cancer therapies. I prepared for presentation 25 cases with poor prognosis or terminal illness who had either enjoyed long-term survival or tumor regression while following my program. After the session, Dr. Friedman suggested we pursue a pilot study of our methods in 10 patients suffering inoperable adenocarcinoma of the pancreas, with survival as the endpoint. Because the standard survival for the disease is so poor, an effect could be seen in a small number of patients in a short period of time. Nestec (the Nestle Corporation) agreed to fund the trial, which began in January 1994. The study has been completed and was published in Nutrition and Cancer, June, 1999;33(2). Of 11 patients followed in the trial, eight of 11 suffered stage four disease. Nine of 11 (81%) lived one year, five of 11 lived two years (45%), and four of 11 lived three years (36%). Two are alive and well with no signs of disease, one at 3.5 years and one at 4.5 years. In comparison, in a recent trial of the newly-approved drug gemcitabine, of 126 patients with pancreatic cancer not a single patient lived longer than 19 months. As a result of the pilot study, the National Cancer Institute approved $1.4 million over five years for a large scale, randomized clinical trial comparing my nutritional therapy against gemcitabine in the treatment of inoperable pancreatic cancer. This study has full FDA approval and is being conducted under the Department of Oncology and the Department of Surgical Oncology at Columbia Presbyterian Medical Center in New York. The trial is the outgrowth of a Congressional hearing last summer encouraging intensive government evaluation of promising alternative cancer treatments, and is currently up and running. We are accruing patients right now for the study, and interested patients can learn more about this study and its objectives from Michelle Gabay, in the office of Dr. John Chabot, M.D., Chief of Surgical Oncology at Columbia, phone (212) 305-9468." [source: http://www.dr-gonzalez.com/clinical_pearls.htm ]     a bit is written about that therapy here, as well: http://nccam.nih.gov/about/offices/od/directortestimony/0607 (I first found out about this link from here: http://cancerforums.net/viewtopic.php?t=3247 ) Wunderchu Tue, 13 Mar 2007 00:00:00 GMT